What is Metavention?
Metavention is a specialized medical device firm dedicated to innovating treatments for hypertension and associated metabolic diseases. At the core of its technology is the iRF Denervation System, which utilizes radio frequency energy to disrupt overactive sympathetic nerves in the renal artery. This procedure is designed to provide a durable, non-pharmacological solution for patients who struggle to manage high blood pressure through traditional medication alone. By focusing on the sympathetic nervous system, Metavention aims to address the root physiological drivers of hypertension, potentially offering a transformative alternative for patients and healthcare providers worldwide. The company maintains a rigorous commitment to clinical research, ensuring that its therapeutic solutions meet the highest safety and efficacy standards required for global market adoption.
How much funding has Metavention raised?
Metavention has raised a total of $42M across 2 funding rounds:
Series B
$12M
Series C
$30M
Series B (2014): $12M, investors not publicly disclosed
Series C (2017): $30M led by Horowitz Group, Versant Ventures, New Enterprise Associates, and Sanderling Ventures
Key Investors in Metavention
Versant Ventures
Versant Ventures is a global venture capital firm that partners with entrepreneurs to build innovative biotechnology companies, leveraging over 5.5 billion dollars in assets under management.
New Enterprise Associates
New Enterprise Associates is a prominent venture capital firm established in 1977, dedicated to providing early-stage and growth-stage support to entrepreneurs building transformative businesses.
Sanderling Ventures
Sanderling Ventures is a pioneering investment firm founded in 1979 that specializes in the creation and active management of early-stage biomedical and medical device companies.
What's next for Metavention?
With the support of its recent capital injection, Metavention is poised to advance its clinical trial pipeline, focusing on the long-term safety and efficacy of the iRF Denervation System. The company's strategic roadmap involves navigating complex regulatory pathways and gathering the robust clinical data necessary to secure market authorization in key international territories. As the firm moves forward, it will likely prioritize the scaling of its manufacturing capabilities and the establishment of strategic partnerships with major hospital networks to facilitate the adoption of its renal denervation technology. The focus remains on demonstrating clear patient outcomes, which will be critical for long-term commercial success and potential future exit opportunities in the competitive medical device landscape.
See full Metavention company page
